{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T01:15:08Z","timestamp":1728177308462},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chirurgie"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00104-023-01849-2","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T10:05:12Z","timestamp":1681293912000},"page":"890-898","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Diagnostik, Therapie und Nachsorge des Analkarzinoms","Diagnostics, treatment and aftercare of anal cancer"],"prefix":"10.1007","volume":"94","author":[{"given":"Felix","family":"Aigner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"1849_CR1","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Analkarzinom (Diagnostik, Therapie und Nachsorge von Analkanal- und Analrandkarzinomen), Langversion 1.2, 2020, AWMF Registernummer: 081\/004OL, https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/analkarzinom\/ (last accessed on 10 January 2023)"},{"key":"1849_CR2","unstructured":"Amin MB, Greene FL, Edge SB et al (Hrsg) AJCC cancer staging manual, 8.\u00a0Aufl. Springer International Publishing, 2017"},{"key":"1849_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s00761-020-00734-5","volume":"26","author":"N Buttmann-Schweiger","year":"2020","unstructured":"Buttmann-Schweiger\u00a0N, Kraywinkel\u00a0K (2020) Epidemiology of cancer of anus and anal canal in Germany. Onkologe 26:306\u2013310","journal-title":"Onkologe"},{"key":"1849_CR4","unstructured":"Robert Koch-Institut Zentrum f\u00fcr Krebsregisterdaten. https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Krebsarten\/Analkrebs\/analkrebs_node.html. Zugegriffen: 10. Jan. 2023"},{"key":"1849_CR5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/CCO.0b013e328354cc4d","volume":"24(4","author":"Y Jiang","year":"2012","unstructured":"Jiang\u00a0Y, Ajani\u00a0JA (2012) Anal margin cancer: current situation and ongoing trials. Curr Opin Oncol 24(4:448\u2013453","journal-title":"Curr Opin Oncol"},{"key":"1849_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1473-3099(17)30653-9","volume":"18","author":"C Lin","year":"2018","unstructured":"Lin\u00a0C, Franceschi\u00a0S, Clifford\u00a0GM (2018) Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a\u00a0systematic review and meta-analysis. Lancet Infect Dis 18:198\u2013206","journal-title":"Lancet Infect Dis"},{"key":"1849_CR7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/ijc.25080","volume":"127","author":"KG Sunesen","year":"2010","unstructured":"Sunesen\u00a0KG, Norgaard\u00a0M, Thorlacius-Ussing\u00a0O, Laurberg\u00a0S (2010) Immunosuppressive disorders and risk of anal squamous cell carcinoma: a\u00a0nationwide cohort study in Denmark, 1978\u20132005. Int J Cancer 127:675\u2013684","journal-title":"Int J Cancer"},{"issue":"1","key":"1849_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ijc.33185","volume":"148","author":"GM Clifford","year":"2020","unstructured":"Clifford\u00a0GM, Georges\u00a0D, Shiels\u00a0MS et al (2020) A\u00a0meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale. Int J Cancer 148(1):38\u201347","journal-title":"Int J Cancer"},{"key":"1849_CR9","first-page":"217","volume":"118","author":"R Siegel","year":"2021","unstructured":"Siegel\u00a0R, Werner\u00a0RN, Koswig\u00a0S, Gaskins\u00a0M, R\u00f6del\u00a0C, Aigner\u00a0F (2021) on behalf of the Anal Cancer Guideline Group: Clinical practice guideline: Anal cancer\u2014diagnosis, treatment and follow-up. Dtsch Arztebl Int 118:217\u2013224","journal-title":"Dtsch Arztebl Int"},{"key":"1849_CR10","doi-asserted-by":"publisher","first-page":"20170370","DOI":"10.1259\/bjr.20170370","volume":"90","author":"A Mahmud","year":"2017","unstructured":"Mahmud\u00a0A, Poon\u00a0R, Jonker\u00a0D (2017) PET imaging in anal canal cancer: a\u00a0systematic review and meta-analysis. Br J Radiol 90:20170370","journal-title":"Br J Radiol"},{"key":"1849_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(17)30071-2","volume":"18","author":"R Glynne-Jones","year":"2017","unstructured":"Glynne-Jones\u00a0R, Sebag-Montefiore\u00a0D, Meadows\u00a0HM et al (2017) Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a\u00a0post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol 18:347\u2013356","journal-title":"Lancet Oncol"},{"key":"1849_CR12","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.3390\/cancers13102451","volume":"13","author":"AC Lef\u00e8vre","year":"2021","unstructured":"Lef\u00e8vre\u00a0AC et al (2021) The Clinical Value of Measuring Circulating HPV DNA during Chemo-Radiotherapy in Squamous Cell Carcinoma of the Anus. Cancers 13:2451","journal-title":"Cancers"},{"key":"1849_CR13","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1200\/JCO.19.03266","volume":"38","author":"S Rao","year":"2020","unstructured":"Rao\u00a0S, Sclafani\u00a0F, Eng\u00a0C et\u00a0al (2020) International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAact. J\u00a0Clin Oncol 38:2510\u20132518","journal-title":"J Clin Oncol"},{"key":"1849_CR14","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, AWMF): S3-Leitlinie Palliativmedizin f\u00fcr Patienten mit einer nichtheilbaren Krebserkrankung, Langversion 2.1 \u2013 Januar 2020, AWMFRegisternummer: 128\/001OL. www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Palliativmedizin\/Version_2\/LL_Palliativmedizin_Langversion_2.2.pdf (last accessed on 10 January 2023)."}],"container-title":["Die Chirurgie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-023-01849-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00104-023-01849-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-023-01849-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T17:02:04Z","timestamp":1695747724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00104-023-01849-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1849"],"URL":"https:\/\/doi.org\/10.1007\/s00104-023-01849-2","relation":{},"ISSN":["2731-6971","2731-698X"],"issn-type":[{"value":"2731-6971","type":"print"},{"value":"2731-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"22 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>F.\u00a0Aigner: <\/b>A. Finanzielle Interessen: BD Referentenhonorar Satellitensymposium St. Gallen (European Colorectal Congress),\u00a012\/2022; Takeda Referentenhonorare (Expertenmeeting Kurzdarmsyndrom, chronisch-entz\u00fcndliche Darmerkrankungen), 2020\u20132023; AbbVie Referentenhonorar (Biologikacircle), 2022. \u2013\u00a0B. Nichtfinanzielle Interessen: Chefarzt Chirurgische Abteilung, Barmherzige Br\u00fcder Krankenhaus Graz, \u00d6sterreich, apl Professur Charit\u00e9\u00a0\u2013 Universit\u00e4tsmedizin Berlin; Wahlarzt f\u00fcr Allgemein- und Viszeralchirurgie, Graz, \u00d6sterreich; allgemein beeideter und gerichtlich zertifizierter Sachverst\u00e4ndiger f\u00fcr Allgemein- und Viszeralchirurgie in \u00d6sterreich; Vorsitzender der Arbeitsgemeinschaft f\u00fcr Coloproktologie e.\u202fV. \u00d6sterreich; kooptiertes Vorstandsmitglied der Deutschen Gesellschaft f\u00fcr Koloproktologie.<b> R.\u00a0Siegel: <\/b>A. Finanzielle Interessen: R. Siegel gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B. Nichtfinanzielle Interessen: Angestellter in Klinik f\u00fcr Allgemein\u2011, Viszeral- und Onkologische Chirurgie, Helios Klinikum Berlin-Buch, Berlin, Deutschland, Fakult\u00e4t f\u00fcr Gesundheit, Universit\u00e4t Witten\/Herdecke, Witten, Deutschland.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}